L. Lemke

Mind the gap: Data availability, accessibility, transparency, and credibility during the COVID-19 pandemic, an international comparative appraisal

E. Kondilis, Fabia Hannan Mone, R. B. Hasan, 2022, medRxiv.

GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods

J. Poetzl, O. von Richter, Lena Lemke, 2019, Expert opinion on biological therapy.

GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar

O. von Richter, Davide Guerrieri, T. O’Reilly, 2022, Expert opinion on biological therapy.

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

A. Blauvelt, C. Leonardi, Ines Brueckmann, 2021, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

A. Blauvelt, C. Leonardi, Ines Brueckmann, 2021, BioDrugs.